Who
R. Sanders Williams
Director
Company insider
Files Form 4 as: Director, Tenaya Therapeutics; Director, Labcorp Holdings; Director, Amgen; Director, Bristol-Myers Squibb.
In numbers
- Trades disclosed
- 161
- Buys
- 0
- Sells
- 24
- Bought
- $0
- Sold
- $3.9M
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 29 Sep 2006
- Last trade
- 28 May 2026
- Last filed
- 29 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 28 May 2026filed 29 May 2026 | TNYA Tenaya Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —120,000 at $0.00 | filing |
| 28 May 2026filed 29 May 2026 | TNYA Tenaya Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —120,000 at $0.00 | filing |
| 29 May 2025filed 30 May 2025 | TNYA Tenaya Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —107,400 at $0.00 | filing |
| 18 Oct 2024filed 21 Oct 2024 | TNYA Tenaya Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —34,000 at $0.00 | filing |
| 7 Feb 2024filed 8 Feb 2024 | LH Labcorp Holdingsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —947 at $0.00 | filing |
| 7 Feb 2024filed 8 Feb 2024 | LH Labcorp HoldingsDiagnostics & Labs | SEC FORM 4 Code M | —947 | filing |
| 6 Feb 2024filed 8 Feb 2024 | LH Labcorp Holdingsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —236 at $0.00 | filing |
| 9 Jun 2023filed 12 Jun 2023 | TNYA Tenaya Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,532 at $0.00 | filing |
| 19 May 2023filed 23 May 2023 | AMGN AmgenBiotechnology | SEC FORM 4 Code A | —939 at $0.00 | filing |
| 11 Feb 2023filed 14 Feb 2023 | LH Labcorp Holdingsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —742 at $0.00 | filing |
| 11 Feb 2023filed 14 Feb 2023 | LH Labcorp HoldingsDiagnostics & Labs | SEC FORM 4 Code M | —742 | filing |
| 7 Feb 2023filed 9 Feb 2023 | LH Labcorp Holdingsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —849 at $0.00 | filing |
| 22 Aug 2022filed 22 Aug 2022 | AMGN AmgenBiotechnology | SEC FORM 4 Sold | $50K200 at $249.96 | filing |
| 10 Jun 2022filed 13 Jun 2022 | TNYA Tenaya Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,727 at $0.00 | filing |
| 23 May 2022filed 23 May 2022 | AMGN AmgenBiotechnology | SEC FORM 4 Sold | $150K600 at $250.00 | filing |
| 17 May 2022filed 19 May 2022 | AMGN AmgenBiotechnology | SEC FORM 4 Code A | —855 at $0.00 | filing |
| 25 Mar 2022filed 29 Mar 2022 | LH Labcorp HoldingsDiagnostics & Labs | SEC FORM 4 Sold | $156K572 at $272.98 | filing |
| 11 Feb 2022filed 15 Feb 2022 | LH Labcorp Holdingsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —742 at $0.00 | filing |
| 11 Feb 2022filed 15 Feb 2022 | LH Labcorp Holdingsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —742 at $0.00 | filing |
| 2 Feb 2022filed 4 Feb 2022 | LH Labcorp Holdingsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —771 at $0.00 | filing |
News
Amgen Has the Drugs and the Dividend. Now It Needs the GrowthAMGN · insidermonkey.com · 19 Oct 2026Labcorp To Acquire BioReference Health Assets; OPKO Shares Rise 7.35%LH · rttnews.com · 15 Oct 2026Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference HealthLH · prnewswire.com · 15 Oct 2026Biogen (BIIB) vs Amgen (AMGN) and Gilead (GILD): Which Big Pharma Stock is a Better Buy?AMGN · insidermonkey.com · 13 Oct 2026Labcorp (LH): Is Its Earnings Discount Worth the Growing Investment Bill?LH · insidermonkey.com · 12 Oct 2026Amgen (AMGN) and Johnson & Johnson (JNJ) Catch Jim Cramer's Eye for Different ReasonsAMGN · insidermonkey.com · 8 Oct 2026
0 headlines in the last 90 days name R. Sanders Williams; 6 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.